Baricitinib is in development for the treatment of adults with moderate to severe atopic dermatitis (AD) which is also known as eczema or atopic eczema. AD is a chronic inflammatory skin disease that affects both children and adults and is characterized by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Baricitinib acts by selectively and reversibly blocking the janus-associated kinase (JAK) enzymes that mediate the pathways involved in the inflammatory process in AD and other inflammatory diseases. Baricitinib is taken orally and is currently licensed for the treatment of moderate to severe active rheumatoid arthritis in adult patients that have not responded well to other therapies. If licensed, baricitinib will offer an additional treatment option for adults with moderate to severe AD.
Oleogel-S10 is a topical gel and is being developed as a prescription medicine as for EB, for which there are limited treatment options. Oleogel-S10 causes the keratinocytes (cells that regenerate the outer layer of the skin) to migrate (move across the wound) and become mature epithelial skin cells, resulting in rapid wound healing. If licensed, oleogel-S10 will offer a treatment option for wound care in patients with EB who currently have limited therapies available.